Market Brief

The articles are produced in Chinese only.

Author

梁文軒先生 (Eddie Leung)
助理經理

現任職輝立助理經理,對投資股票、期權經驗豐富。本人樂意為客戶提供投資分析及買賣策略。歡迎各位來電交流心得。
Phone:
3667 0668

石藥集團(1093)

Thursday, January 19, 2017 Views7856

石藥集團(1093)有限公司,從事製造及銷售藥品,生產基地主要在河北省石家莊

市。是國內主要醫藥製造商之一。從2004年以來連續十一度入選“中國500最具

價值品牌。連續三次躋身中國企業500強。集團上半年取得3個新產品的生產

批准,盈利能力有望進一步提升。截至2016年9月30日,集團收入環比增長8.8%

至HK $ 9.25B。淨收入增長26%至HK $ 1.57B。每股基本盈利扣除非經常性項

目由HK $ 0.21增加至HK $ 0.26。業績表現亮麗,高盛將公司目標由8﹒84元

上調至9﹒42元,重申「買入」評級。隨著中國人口老齡化進程的加快,有利

公司的業務,料可看高一綫。

 

買賣策略

買入: $8.1-8.2 收集   目標價: $9    止蝕價: $7.8

 

本人梁文軒為證監會持牌人士。截至本評論文章發表日止,本人及/⁠⁠或其有聯繫

者並無持有全部提及之證券的所有相關財務權益。

 

This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk. Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email : businessenquiry@phillip.com.hk

Enquiry & Support
Branches
The Complaint Procedures
About Us
Phillip Securities Group
Join Us
Phillip Network
Phillip Post
Phillip Channel
Latest Promotion
E-Check
Login
Investor Notes
Free Subscribe
Contact Us